| Theme | Tumors and bone mineral metabolism | |
|---|---|---|
| Title | New therapeutic agents for bone metastasis | |
| Publish Date | 2014/01 | |
| Author | Itsuro Endo | Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Medical Sciences |
| [ Summary ] | Breast cancer and prostate cancer have a predilection for spreading to the bones. Patients with bone metastasis frequently suffer bone related events. These complications have relevance to low QOL and poor prognosis. Recently, some therapeutic targets, including the RANK-RANKL axis for bone metastasis have become clear. Based on these basic data, drugs are under development and anti-RANKL antibody has become available. Clinical research data warrant the use of anti-RANKL neutralizing antibody as a specific and more effective therapeutic agent for the treatment of bone metastasis in these patients. Cathepsin K inhibitors and Src inhibitors are also expected to become important new options for the treatment of bone metastasis. | |